Patents Assigned to CBIO Limited
-
Patent number: 9457062Abstract: The present invention relates to methods for modulating Toll-like receptor signalling in a subject, or in at least one cell, tissue or organ thereof, methods for treating or preventing a disease or condition in a subject, methods for modulating the production and/or secretion of one or more immunomodulators in a subject, or at least one cell, tissue or organ thereof, wherein said methods involve the administration of chaperonin 10, and wherein the chaperonin 10 associates with a Toll-like receptor in an activation cluster. Also contemplated are associated compositions and uses thereof.Type: GrantFiled: July 11, 2006Date of Patent: October 4, 2016Assignee: CBIO LIMITEDInventors: Barbara J. Johnson, Caroline A. Dobbin, Dean J. Naylor, Linda A. Ward, Inge E. A. Flesch, Christopher B. Howard
-
Patent number: 9234019Abstract: The present invention relates to isolated Cpn10 polypeptides possessing an increased affinity for a PRR ligand compared to Ala Cpn10 polypeptide. In a further embodiment, the present invention also relates to modified chaperonin 10 polypeptides, and to nucleic acids encoding the same and to compositions comprising such polypeptides and uses thereof.Type: GrantFiled: April 9, 2009Date of Patent: January 12, 2016Assignee: CBio LimitedInventors: Dean Jason Naylor, Richard James Brown, Christopher Bruce Howard, Christopher John De Bakker, Linda Alisson Ward, Jeanette Elizabeth Stok, Andrew Leigh James, Daniel Scott Lambert, Kylie Jane Ralston, Walter Rene Antonius Van Heumen
-
Patent number: 8933033Abstract: The invention relates generally to chaperonin 10 N-terminal variants. More specifically, the invention relates to chaperonin 10 N-terminal variants with enhanced immunomodulatory capacity and/or enhanced binding affinity for pathogen-associated molecular patterns (PAMPs) and/or damage-associated molecular patterns (DAMPs).Type: GrantFiled: October 8, 2010Date of Patent: January 13, 2015Assignee: CBio LimitedInventors: Dean Jason Naylor, Richard James Brown, Christopher Bruce Howard, Christopher John De Bakker, Jeanette Elizabeth Stok, Andrew Leigh James, Daniel Scott Lambert, Kylie Jane Ralston, Walter Rene Antonius Van Heumen, Linda Allison Ward
-
Patent number: 8796225Abstract: The present invention relates to the use of chaperonin 10 to modulate the function of antigen presenting cells. More particularly the invention resides in the modulation of cell surface expression of MHC molecules such as HLA.Type: GrantFiled: March 1, 2007Date of Patent: August 5, 2014Assignee: CBIO LimitedInventors: Barbara Jane Johnson, Caroline Amanda Dobbin, Inge E A Flesch
-
Publication number: 20120328635Abstract: The invention relates generally to chaperonin 10 N-terminal variants. More specifically, the invention relates to chaperonin 10 N-terminal variants with enhanced immunomodulatory capacity and/or enhanced binding affinity for pathogen-associated molecular patterns (PAMPs) and/or damage-associated molecular patterns (DAMPs).Type: ApplicationFiled: October 8, 2010Publication date: December 27, 2012Applicant: CBio LimitedInventors: Dean Jason Naylor, Richard James Brown, Christopher Bruce Howard, Christopher John De Bakker, Jeanette Elizabeth Stok, Andrew Leigh James, Daniel Scott Lambert, Kylie Jane Ralston, Walter Rene Antonius Van Heumen, Linda Allison Ward
-
Publication number: 20120014998Abstract: The present invention relates to isolated Chaperonin 10 polypeptides possessing immunomodulatory activity, but lacking, or substantially lacking, protein folding activity.Type: ApplicationFiled: June 7, 2011Publication date: January 19, 2012Applicant: CBIO LIMITEDInventors: DEAN JASON NAYLOR, BARBARA JANE JOHNSON, CAROLINE AMANDA DOBBIN, CHRISTOPHER BRUCE HOWARD, LINDA ALLISON WARD
-
Patent number: 8067361Abstract: The invention is directed to the use of cpn10 in transplantation and particularly to treatment and/or prevention of graft versus host disease. The invention provides a method of administration of cpn10 to a donor and/or recipient animal or cells, tissues or organs derived from the donor, although in a particularly advantageous form treatment of both the donor and recipient animal. The method may further include the administration to the donor and/or recipient animal at least one other immunosuppressive agent to prevent or alleviate graft versus host disease.Type: GrantFiled: October 1, 2009Date of Patent: November 29, 2011Assignee: CBIO LimitedInventors: Geoffrey R. Hill, Tatjana Banovic, Halle Morton, Alice Christina Cavanagh
-
Publication number: 20110243921Abstract: Disclosed herein, in certain embodiments, are methods and compositions for the prevention and treatment of autoimmune disease. Further disclosed herein, in certain embodiments, are methods for the prevention and treatment of cutaneous lupus erythematosus. Additionally disclosed herein, in certain embodiments, are compositions for the prevention and treatment of cutaneous lupus erythematosus.Type: ApplicationFiled: March 30, 2010Publication date: October 6, 2011Applicant: CBIO LIMITEDInventors: Hans-Joachim Anders, Dean Jason Naylor, Richard James Brown, Walter Rene Antonius Van Heumen
-
Patent number: 7977458Abstract: A novel granule dispersion composition which comprises water and, dispersed therein, a finely pulverized, sparingly water-soluble substance. The granule dispersion composition is prepared by dispersing in water a granular material which comprises a specific substance sparingly soluble in water, a polymer, and an oil and has an average particle diameter of 1 ?m or smaller and in which the ratio of the total weight of the polymer and oil to the weight of the specific substance is 1.5 or higher.Type: GrantFiled: August 31, 2006Date of Patent: July 12, 2011Assignee: CBIO LimitedInventors: Dean Jason Naylor, Barbara Jane Johnson, Caroline Amanda Dobbin, Christopher Bruce Howard, Linda Allison Ward
-
Patent number: 7951613Abstract: Methods of use of Chaperonin 10 (Cpn10) are provided for regulating Toll-like receptor signaling and/or Toll-like receptor inducible immunomodulator secretion. Cpn10 negatively regulates Toll-like receptor agonist-induced pro-inflammatory cytokine and chemokine secretion, examples being IL-6 and RANTES, respectively. Cpn10 positively regulates Toll-like receptor agonist-induced anti-inflammatory cytokine and chemokine secretion, an example being IL-10. These immunoregulatory activities of Cpn10 may be useful in the treatment of diseases, disorders and conditions resulting from excessive pro-inflammatory cytokine and chemokine secretion. This invention also relates to producing, designing and/or screening Cpn10 agonists and antagonists according to their ability to regulate Toll-like receptor signaling and/or Toll-like receptor inducible immunomodulator secretion.Type: GrantFiled: September 3, 2009Date of Patent: May 31, 2011Assignee: CBIO LimitedInventors: Barbara Jane Johnson, Andreas Suhrbier, Dean Jason Naylor, Caroline Amanda Dobbin, Christopher Bruce Howard
-
Publication number: 20110082073Abstract: The present invention relates to isolated Cpn10 polypeptides possessing an increased affinity for a PRR ligand compared to Ala Cpn10 polypeptide. In a further embodiment, the present invention also relates to modified chaperonin 10 polypeptides, and to nucleic acids encoding the same and to compositions comprising such polypeptides and uses thereof.Type: ApplicationFiled: April 9, 2009Publication date: April 7, 2011Applicant: CBIO LIMITEDInventors: Dean Jason Naylor, Richard James Brown, Christopher Bruce Howard, Christopher John De Bakker, Linda Alisson Ward, Jeanette Elizabeth Stok, Andrew Leigh James, Daniel Scott Lambert, Kylie Jane Ralston, Walter Rene Antonius Van Heumen
-
Publication number: 20100256059Abstract: The present invention relates to the use of chaperonin 10 to modulate the function of antigen presenting cells. More particularly the invention resides in the modulation of cell surface expression of MHC molecules such as HLA.Type: ApplicationFiled: March 1, 2007Publication date: October 7, 2010Applicant: CBIO LIMITEDInventors: Barbara Jane Johnson, Caroline Amanda Dobbin, Inge E A Flesch
-
Publication number: 20090325882Abstract: Methods of use of Chaperonin 10 (Cpn10) are provided for regulating Toll-like receptor signaling and/or Toll-like receptor inducible immunomodulator secretion. Cpn10 negatively regulates Toll-like receptor agonist-induced pro-inflammatory cytokine and chemokine secretion, examples being IL-6 and RANTES, respectively. Cpn10 positively regulates Toll-like receptor agonist-induced anti-inflammatory cytokine and chemokine secretion, an example being IL-10. These immunoregulatory activities of Cpn10 may be useful in the treatment of diseases, disorders and conditions resulting from excessive pro-inflammatory cytokine and chemokine secretion. This invention also relates to producing, designing and/or screening Cpn10 agonists and antagonists according to their ability to regulate Toll-like receptor signaling and/or Toll-like receptor inducible immunomodulator secretion.Type: ApplicationFiled: September 3, 2009Publication date: December 31, 2009Applicant: CBIO LIMITEDInventors: BARBARA JANE JOHNSON, ANDREAS SUHRBIER, DEAN JASON NAYLOR, CAROLINE AMANDA DOBBIN, CHRISTOPHER BRUCE HOWARD
-
Patent number: 7618935Abstract: The invention is directed to the use of cpnl0 in transplantation and particularly to treatment and/or prevention of graft versus host disease. The invention provides a method of administration of cpn10 to a donor and/or recipient animal or cells, tissues or organs derived from the donor, although in a particularly advantageous form treatment of both the donor and recipient animal. The method may further include the administration to the donor and/or recipient animal at least one other immunosuppressive agent to prevent or alleviate graft versus host disease.Type: GrantFiled: November 6, 2003Date of Patent: November 17, 2009Assignee: CBIO LimitedInventors: Geoffrey R. Hill, Tatjana Banovic, Halle Morton, Alice Christina Cavanagh
-
Publication number: 20090087410Abstract: The present invention relates to a method for inhibiting a hypersensitivity reaction in a subject, wherein said method comprises administering an effective amount of chaperonin (10).Type: ApplicationFiled: October 20, 2006Publication date: April 2, 2009Applicant: CBio LimitedInventors: Andrew John Hubert Gearing, Barbara Jane Johnson
-
Publication number: 20090047240Abstract: The present invention relates to methods for modulating Toll-like receptor signalling in a subject, or in at least one cell, tissue or organ thereof, methods for treating or preventing a disease or condition in a subject, methods for modulating the production and/or secretion of one or more immunomodulators in a subject, or at least one cell, tissue or organ thereof, wherein said methods involve the administration of chaperonin 10, and wherein the chaperonin 10 associates with a Toll-like receptor in an activation cluster. Also contemplated are associated compositions and uses thereof.Type: ApplicationFiled: July 11, 2006Publication date: February 19, 2009Applicant: CBio LIMITEDInventors: Barbara J. Johnson, Caroline A. Dobbin, Dean J. Naylor, Linda A. Ward, Inge E.A. Flesch, Christopher B. Howard
-
Publication number: 20060198834Abstract: The invention is directed to the use of cpn10 in transplantation and particularly to treatment and/or prevention of graft versus host disease. The invention provides a method of administration of cpn10 to a donor and/or recipient animal or cells, tissues or organs derived from the donor, although in a particularly advantageous form treatment of both the donor and recipient animal. The method may further include the administration to the donor and/or recipient animal at least one other immunosuppressive agent to prevent or alleviate graft versus host disease.Type: ApplicationFiled: November 6, 2003Publication date: September 7, 2006Applicant: CBio LimitedInventors: Geoffrey Hill, Tatjana Banovic